ArticleScientific reports2026
Extrapancreatic extension modifies chemotherapy benefit in resected pancreatic ductal adenocarcinoma: a population-based cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of extrapancreatic extension (EPE) on the benefit of chemotherapy remains unclear. We analyzed 22,045 surgically treated patients with resected PDAC from the SEER database (2004–2022). Variable importance was assessed using Random Survival Forest models with SHAP and permutation methods. Cox proportional hazards models evaluated survival associations and EPE-chemotherapy interactions on multiplicative and additive scales, with Fine-Gray competing risk models for sensitivity analyses. Variable importance analysis identified chemotherapy, EPE, and N stage as the most influential prognostic factors. Chemotherapy absence increased disease-specific mortality (adjusted HR 1.45, 95% CI 1.39–1.52, p < 0.001), while EPE conferred additional risk (adjusted HR 1.25, 95% CI 1.19–1.31, p < 0.001). Notably, within the EPE stratum, chemotherapy absence increased mortality risk by 83% (adjusted HR 1.83, 95% CI 1.75–1.91) versus 34% (adjusted HR 1.34, 95% CI 1.23–1.46) in non-EPE patients. EPE patients receiving chemotherapy achieved comparable adjusted 3-year disease-specific survival to non-EPE patients without chemotherapy (39.5% vs 35.0%). Significant multiplicative interaction (HR 1.37, 95% CI 1.24–1.50, p < 0.001) and additive interaction (RERI 0.63, 95% CI 0.51–0.76, p < 0.001) were observed, with consistent patterns across tumor size categories validated in competing risk analyses. This population-based analysis revealed EPE as an independent adverse prognostic factor in resected PDAC and a significant EPE-chemotherapy interaction on both multiplicative and additive scales across tumor size categories. Despite conferring worse prognosis, EPE-positive patients receiving chemotherapy achieved survival comparable to that of EPE-negative patients without chemotherapy, underscoring the importance of ensuring receipt of chemotherapy in EPE-positive disease. These findings support the need to re-evaluate the role of EPE in staging systems; however, prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.